by North Woods | Sep 1, 2026 | Portfolio Spotlights
In oncology, time is one of the most precious resources a patient has. Yet for many cancer patients, treatment decisions are still made with limited information about whether a therapy is likely to work for them. Immunotherapies have transformed what is possible in...
by North Woods | Aug 5, 2026 | Perspectives
Recently named Chair-Elect of the NVCA, Clarevia Ventures’ Founding Partner reflects on venture capital, public policy, and the importance of having a Midwest voice at the national table. Venture capital has helped shape some of the most important companies in the...
by North Woods | Jul 30, 2026 | Firm News
MADISON, Wis., July 21, 2026 — Clarevia Ventures today announced that Cheryl R. Blanchard, Ph.D., former President and CEO and current Executive Chair of Anika Therapeutics, has joined the firm as Executive in Residence (EIR). In this role, Blanchard will work...
by North Woods | Jun 23, 2026 | Blog, Firm News
MADISON, Wis., June 23, 2026 — Clarevia Ventures today announced the appointment of Margaret Kaczor Andrew as Venture Partner. In this role, Kaczor Andrew will focus on sourcing, evaluating, and supporting investments across medical devices, clinical technologies, and...
by North Woods | May 29, 2026 | Blog, Why We Invested
By: Scott Button, Partner at Clarevia Ventures RiverMark Medical recently announced a $20 million Series D financing led by Andera Partners to develop the FloStent™ System, an investigational device designed to offer a non-surgical, reversible, office-based treatment...
